SAN DIEGO, April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC). While this does not mean the method of divestment has been finalized, the company is pleased to reach an agreement with the EC on specific divestment options as it represents an important milestone in the process. Illumina continues to explore divesting GRAIL throug ...

SAN DIEGO, April 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and ope ...

Illumina公司收购案裁决 - 欧洲法院高级顾问批评了欧盟委员会对Illumina收购案的裁决[2] - 欧盟委员会在2021年阻止了Illumina对Grail的收购，但被指责未正确应用相关法规[4] - 欧洲法院高级顾问表示，基于此裁决的所有决定应该被撤销，包括Illumina对Grail的收购[5] - Illumina对欧盟委员会的裁决表示不满，认为其对此次收购的管辖权主张是不当的[7]

Illumina公司股票表现 - Illumina（ILMN）是生物技术领域的一家基因测序公司，其股价在周一表现出色，比标普500指数上涨了近3%[1] - Illumina目前拥有近1.59亿股流通股，市值接近220亿美元[3] Illumina公司高管行为 - Illumina的CEO Jacob Thaysen在上周四进行了股票购买，购买了7300股公司股票，使其持股数量翻倍，目前持有14861股[2] - 公司高管自己购买公司股票通常会激励投资者，显示对公司未来的信心[4] - Thaysen的购买虽然规模不大，但他增加持股数量的举动可能传达出一定的信息[5] Illumina公司未来展望 - 对于Illumina的投资者来说，更重要的是公司未来的表现[6]

Illumina (ILMN) possesses promising opportunities to advance the next-generation sequencing ecosystem. Adverse macroeconomic challenges remain a major downside. The stock carries a Zacks Rank #3 (Hold) currently.Illumina is currently keeping up well with the goals to strengthen its foothold in the multi-billion gene sequencing worldwide market with some highly competitive products in its existing portfolio and pipeline. Further, the company is developing sample-to-answer solutions to catalyze adoption in th ...

财务数据 - Illumina的2022年收入增长1%，达到46亿美元[190] - 2022年毛利率为64.8%，较2021年的69.7%下降[191] - 2022年营业亏损达到42亿美元，较2021年的1.23亿美元增加[192] - 2022年，公司产品收入占总收入的86.2%，服务和其他收入占13.8%[197] - 2022年，公司现金、现金等价物和短期投资总额为20亿美元[196] - 2022年，核心 Illumina 的消耗品收入为32.46亿美元，仪器收入为7.29亿美元[198] - 2022年，GRAIL 的服务和其他收入为5.5亿美元，消除因素为2.4亿美元[198] - 2022年，核心 Illumina 毛利率为68.2%，GRAIL 毛利率不具有意义[200] - 2022年，核心 Illumina 研发费用增加13%[203] - 2022年，GRAIL 的销售和管理支出为4.48亿美元[206] 财务策略 - 公司于2022年12月13日发行了总额为5亿美元的期限票据和总额为5亿美元的期限票据[216] - 公司于2023年1月4日签订了新的信贷协议，提供了总额为7.5亿美元的五年期无担保循环信贷设施[219] - 公司预计当前现金、现金等价物和短期投资足以支持未来至少12个月的资本和运营需求[224] - 2022年投资支出总额为5.91亿美元，主要用于设施投资[230] - 2022年融资活动中，融资活动提供的净现金为10亿美元[232] 公司运营 - Illumina公司2023年1月1日的产品收入为45.84亿美元[282] - 2023年，Illumina公司的研发支出为13.21亿美元[282] - Illumina公司2023年1月1日的现金及现金等价物为20.11亿美元[285] - Illumina公司2023年1月1日的股东权益为65.99亿美元[284] - Illumina公司2023年1月1日的净亏损为44.04亿美元[285] - Illumina公司2023年1月1日的营运活动产生的现金为3.92亿美元[285] - Illumina公司2023年1月1日的投资活动使用的现金为5.91亿美元[285] - Illumina公司2023年1月1日的融资活动提供的现金为10亿美元[285]

Illumina公司财报 - Illumina Inc.（ILMN）2023年第四季度调整后每股收益为14美分，大幅超出Zacks Consensus Estimate的1美分[1] - 公司的调整后每股收益排除了GRAIL预收购净营运亏损对GILTI、利用美国外国税收抵免和额外的非GAAP税收支出等影响[2] - 2023年全年调整后的收益为86美分，较去年同期下降了59.4%，但超出了Zacks Consensus Estimate的13.2%[3] - Illumina在审查的季度内，营收为11.2亿美元，同比增长3.6%（在CER上涨4%），超出Zacks Consensus Estimate 3.1%[4]

Illumina (ILMN) reported $1.12 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 3.6%. EPS of $0.14 for the same period compares to $0.14 a year ago.The reported revenue represents a surprise of +3.11% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.01, the EPS surprise was +1300.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023 GAAP diluted loss per share of $(1.11) for Q4 2023, compared to GAAP diluted loss per share of $(0.89) for Q4 2022 Non-GAAP diluted earnings per share of $0.14 for both Q4 2023 and Q4 2022 GAAP diluted loss per share of ...

AUSTIN, Texas & MENLO PARK, Calif.--(BUSINESS WIRE)--Curative Insurance Company, a pioneering healthcare services company, and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test to eligible insurance plan members. The Galleri test will be available to all members, across all plan types, who are over the age of 50 and to all other members with risk factors for develop ...